BioCentury | Aug 4, 2020
Deals

Dynavax deal gives drug delivery play TriSalus its first therapeutic candidate

Monday’s deal with Dynavax marks TriSalus’ pivot into therapeutics development. TriSalus Life Sciences gained exclusive, worldwide rights to SD-101, a TLR9 agonist, from Dynavax Technologies Corp. (NASDAQ:DVAX). TriSalus will pay Dynavax $5 million up front...
BioCentury | Jul 9, 2020
Product Development

CSL testing coagulation factor blocker in COVID-19 patients; plus vaccine deals and plasma trials

As partnerships aimed at preventing COVID-19 or treating early disease continue to form and expand, CSL has begun testing a blood coagulation factor inhibitor for severe COVID-19. The CSL Behring unit of CSL Ltd. (ASX:CSL)...
BioCentury | Jun 19, 2020
Politics, Policy & Law

House lawmakers call for transparency, independent review for COVID-19 vaccine program

A trio of Democrats on the House Oversight Committee are asking FDA for more information on how the agency plans to evaluate and deploy COVID-19 vaccines, in an effort to ensure the process is transparent,...
BioCentury | May 20, 2020
Product Development

BARDA takes steps to secure supply chain as more companies look to scale up manufacturing

HHS is taking steps to shore up the U.S.’s national supply chain and manufacturing capabilities after global disruptions in the early days of the COVID-19 crisis. The agency’s BARDA has closed a four-year, $354 million...
BioCentury | May 9, 2020
Product Development

China emerging as a leader in COVID-19 vaccines

China’s biotech sector may still be developing, but the COVID-19 crisis has revealed just how swiftly it can bring new vaccines to the clinic. The country has more COVID-19 vaccine candidates in human testing than...
BioCentury | Apr 22, 2020
Product Development

Animal studies show Sinovac’s COVID-19 vaccine is protective, does not cause ADE

Less than one week after entering the clinic, Sinovac became the first company to report animal data supporting its COVID-19 vaccine candidate. Sinovac Biotech Ltd. (NASDAQ:SVA) has PiCoVacc in a Phase I/II study and expects...
BioCentury | Apr 17, 2020
Product Development

BARDA’s $483M commitment to Moderna headlines flurry of COVID-19 vaccine updates

With enrollment complete in the Phase I trial of Moderna’s COVID-19 vaccine, BARDA could spend as much as a half-billion dollars to bring mRNA-1273 across the finish line. The news came amid multiple updates for...
BioCentury | Apr 11, 2020
Emerging Company Profile

Clover: trimerizing fusion proteins

Clover is developing trimerized fusion proteins to target cancer and infectious disease pathways that depend on trimer formation. The company has exclusive, worldwide rights to its Trimer-Tag platform from GenHunter Corp., which was co-founded by...
BioCentury | Mar 27, 2020
Product Development

COVID-19 roundup: biopharmas scramble to reassess clinical timelines; plus CEPI-Dynavax, and emergency approvals for Vero, Fosun

More than a dozen biopharmas Thursday announced delays or disruptions to clinical programs and regulatory timelines as companies begin to turn their attention to managing their trials through the COVID-19 crisis. The setbacks came as...
BC Extra | Dec 17, 2019
Company News

Management Tracks: Dynavax, Merus name CEOs; plus Grail hires a commercial lead, Seres, Zentalis, Nimbus and more

Dynavax Technologies Corp. (NASDAQ:DVAX) named Ryan Spencer as CEO and David Novack president and COO. Spencer succeeds Edward Gray, who retired in August. Both Spencer and Novack had been interim co-presidents since May, when the...
Items per page:
1 - 10 of 509
BioCentury | Aug 4, 2020
Deals

Dynavax deal gives drug delivery play TriSalus its first therapeutic candidate

Monday’s deal with Dynavax marks TriSalus’ pivot into therapeutics development. TriSalus Life Sciences gained exclusive, worldwide rights to SD-101, a TLR9 agonist, from Dynavax Technologies Corp. (NASDAQ:DVAX). TriSalus will pay Dynavax $5 million up front...
BioCentury | Jul 9, 2020
Product Development

CSL testing coagulation factor blocker in COVID-19 patients; plus vaccine deals and plasma trials

As partnerships aimed at preventing COVID-19 or treating early disease continue to form and expand, CSL has begun testing a blood coagulation factor inhibitor for severe COVID-19. The CSL Behring unit of CSL Ltd. (ASX:CSL)...
BioCentury | Jun 19, 2020
Politics, Policy & Law

House lawmakers call for transparency, independent review for COVID-19 vaccine program

A trio of Democrats on the House Oversight Committee are asking FDA for more information on how the agency plans to evaluate and deploy COVID-19 vaccines, in an effort to ensure the process is transparent,...
BioCentury | May 20, 2020
Product Development

BARDA takes steps to secure supply chain as more companies look to scale up manufacturing

HHS is taking steps to shore up the U.S.’s national supply chain and manufacturing capabilities after global disruptions in the early days of the COVID-19 crisis. The agency’s BARDA has closed a four-year, $354 million...
BioCentury | May 9, 2020
Product Development

China emerging as a leader in COVID-19 vaccines

China’s biotech sector may still be developing, but the COVID-19 crisis has revealed just how swiftly it can bring new vaccines to the clinic. The country has more COVID-19 vaccine candidates in human testing than...
BioCentury | Apr 22, 2020
Product Development

Animal studies show Sinovac’s COVID-19 vaccine is protective, does not cause ADE

Less than one week after entering the clinic, Sinovac became the first company to report animal data supporting its COVID-19 vaccine candidate. Sinovac Biotech Ltd. (NASDAQ:SVA) has PiCoVacc in a Phase I/II study and expects...
BioCentury | Apr 17, 2020
Product Development

BARDA’s $483M commitment to Moderna headlines flurry of COVID-19 vaccine updates

With enrollment complete in the Phase I trial of Moderna’s COVID-19 vaccine, BARDA could spend as much as a half-billion dollars to bring mRNA-1273 across the finish line. The news came amid multiple updates for...
BioCentury | Apr 11, 2020
Emerging Company Profile

Clover: trimerizing fusion proteins

Clover is developing trimerized fusion proteins to target cancer and infectious disease pathways that depend on trimer formation. The company has exclusive, worldwide rights to its Trimer-Tag platform from GenHunter Corp., which was co-founded by...
BioCentury | Mar 27, 2020
Product Development

COVID-19 roundup: biopharmas scramble to reassess clinical timelines; plus CEPI-Dynavax, and emergency approvals for Vero, Fosun

More than a dozen biopharmas Thursday announced delays or disruptions to clinical programs and regulatory timelines as companies begin to turn their attention to managing their trials through the COVID-19 crisis. The setbacks came as...
BC Extra | Dec 17, 2019
Company News

Management Tracks: Dynavax, Merus name CEOs; plus Grail hires a commercial lead, Seres, Zentalis, Nimbus and more

Dynavax Technologies Corp. (NASDAQ:DVAX) named Ryan Spencer as CEO and David Novack president and COO. Spencer succeeds Edward Gray, who retired in August. Both Spencer and Novack had been interim co-presidents since May, when the...
Items per page:
1 - 10 of 509